(TECH) Bio-Techne - Ratings and Ratios
Reagents, Instruments, Antibodies, Assays, Controls
Dividends
| Dividend Yield | 0.50% |
| Yield on Cost 5y | 0.43% |
| Yield CAGR 5y | -29.29% |
| Payout Consistency | 92.8% |
| Payout Ratio | 16.6% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 39.1% |
| Value at Risk 5%th | 59.3% |
| Relative Tail Risk | -7.68% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.35 |
| Alpha | -34.29 |
| CAGR/Max DD | -0.17 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.327 |
| Beta | 1.188 |
| Beta Downside | 1.146 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.32% |
| Mean DD | 21.39% |
| Median DD | 18.87% |
Description: TECH Bio-Techne November 03, 2025
Bio-Techne Corp (NASDAQ: TECH) develops and sells life-science reagents, instruments, and services across two segments – Protein Sciences and Diagnostics & Spatial Biology – serving research, clinical diagnostics, and bioprocessing markets worldwide. The Protein Sciences unit supplies cytokines, growth factors, antibodies, and automated proteomic tools (e.g., western blot and multiplex ELISA platforms), while the Diagnostics segment offers molecular-diagnostic assays, exosome-based tests, spatial-genomics kits, and hematology/clinical chemistry reagents.
Key operating metrics from the most recent fiscal year (2023) show total revenue of roughly **$2.5 billion**, a **12 % year-over-year growth** driven largely by the rapid expansion of the spatial-biology market (≈ 20 % CAGR) and increased demand for cell- and gene-therapy reagents. The company generated **$657 million** in Q4 2023 revenue, an operating margin near **15 %**, and maintained a **cash-to-debt ratio of 2.2**, indicating a solid liquidity position. Primary economic drivers include the broader biotech R&D spend cycle, aging demographics that boost diagnostic testing volumes, and the shift toward personalized medicine, all of which underpin long-term demand for Bio-Techne’s product portfolio.
For a deeper quantitative assessment of TECH’s valuation and risk profile, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (78.0m TTM) > 0 and > 6% of Revenue (6% = 73.0m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA -0.09pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 38.21% (prev 43.23%; Δ -5.01pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 251.3m > Net Income 78.0m (YES >=105%, WARN >=100%) |
| Net Debt (249.5m) to EBITDA (224.2m) ratio: 1.11 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (156.4m) change vs 12m ago -2.95% (target <= -2.0% for YES) |
| Gross Margin 65.54% (prev 65.51%; Δ 0.03pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 46.24% (prev 42.82%; Δ 3.42pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.01 (EBITDA TTM 224.2m / Interest Expense TTM 11.8m) >= 6 (WARN >= 3) |
Altman Z'' 4.82
| (A) 0.18 = (Total Current Assets 609.5m - Total Current Liabilities 144.5m) / Total Assets 2.53b |
| (B) 0.43 = Retained Earnings (Balance) 1.08b / Total Assets 2.53b |
| (C) 0.04 = EBIT TTM 118.1m / Avg Total Assets 2.63b |
| (D) 1.82 = Book Value of Equity 1.02b / Total Liabilities 560.3m |
| Total Rating: 4.82 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 58.20
| 1. Piotroski 7.0pt |
| 2. FCF Yield 2.28% |
| 3. FCF Margin 18.41% |
| 4. Debt/Equity 0.20 |
| 5. Debt/Ebitda 1.11 |
| 6. ROIC - WACC (= -5.97)% |
| 7. RoE 3.91% |
| 8. Rev. Trend 59.71% |
| 9. EPS Trend -19.25% |
What is the price of TECH shares?
Over the past week, the price has changed by -1.50%, over one month by +4.13%, over three months by +20.23% and over the past year by -15.80%.
Is TECH a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TECH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 69.2 | 12.1% |
| Analysts Target Price | 69.2 | 12.1% |
| ValueRay Target Price | 65.3 | 5.8% |
TECH Fundamental Data Overview November 25, 2025
P/E Trailing = 125.5714
P/E Forward = 31.0559
P/S = 7.8794
P/B = 4.8769
P/EG = 0.8491
Beta = 1.467
Revenue TTM = 1.22b USD
EBIT TTM = 118.1m USD
EBITDA TTM = 224.2m USD
Long Term Debt = 300.0m USD (from longTermDebt, last quarter)
Short Term Debt = 13.8m USD (from shortTermDebt, last quarter)
Debt = 394.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 249.5m USD (from netDebt column, last quarter)
Enterprise Value = 9.84b USD (9.59b + Debt 394.5m - CCE 145.0m)
Interest Coverage Ratio = 10.01 (Ebit TTM 118.1m / Interest Expense TTM 11.8m)
FCF Yield = 2.28% (FCF TTM 224.1m / Enterprise Value 9.84b)
FCF Margin = 18.41% (FCF TTM 224.1m / Revenue TTM 1.22b)
Net Margin = 6.41% (Net Income TTM 78.0m / Revenue TTM 1.22b)
Gross Margin = 65.54% ((Revenue TTM 1.22b - Cost of Revenue TTM 419.3m) / Revenue TTM)
Gross Margin QoQ = 66.37% (prev 62.72%)
Tobins Q-Ratio = 3.89 (Enterprise Value 9.84b / Total Assets 2.53b)
Interest Expense / Debt = 1.39% (Interest Expense 5.47m / Debt 394.5m)
Taxrate = 20.43% (9.81m / 48.0m)
NOPAT = 94.0m (EBIT 118.1m * (1 - 20.43%))
Current Ratio = 4.22 (Total Current Assets 609.5m / Total Current Liabilities 144.5m)
Debt / Equity = 0.20 (Debt 394.5m / totalStockholderEquity, last quarter 1.97b)
Debt / EBITDA = 1.11 (Net Debt 249.5m / EBITDA 224.2m)
Debt / FCF = 1.11 (Net Debt 249.5m / FCF TTM 224.1m)
Total Stockholder Equity = 2.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.09% (Net Income 78.0m / Total Assets 2.53b)
RoE = 3.91% (Net Income TTM 78.0m / Total Stockholder Equity 2.00b)
RoCE = 5.14% (EBIT 118.1m / Capital Employed (Equity 2.00b + L.T.Debt 300.0m))
RoIC = 4.06% (NOPAT 94.0m / Invested Capital 2.31b)
WACC = 10.03% (E(9.59b)/V(9.98b) * Re(10.40%) + D(394.5m)/V(9.98b) * Rd(1.39%) * (1-Tc(0.20)))
Discount Rate = 10.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.16%
[DCF Debug] Terminal Value 68.63% ; FCFE base≈232.4m ; Y1≈214.8m ; Y5≈194.7m
Fair Price DCF = 15.45 (DCF Value 2.41b / Shares Outstanding 155.8m; 5y FCF grow -9.56% → 3.0% )
EPS Correlation: -19.25 | EPS CAGR: -2.95% | SUE: -0.36 | # QB: 0
Revenue Correlation: 59.71 | Revenue CAGR: 1.67% | SUE: -0.59 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.56 | Chg30d=-0.006 | Revisions Net=-2 | Analysts=12
EPS current Year (2026-06-30): EPS=1.98 | Chg30d=-0.023 | Revisions Net=-5 | Growth EPS=+3.1% | Growth Revenue=+0.4%
EPS next Year (2027-06-30): EPS=2.20 | Chg30d=-0.029 | Revisions Net=-8 | Growth EPS=+10.9% | Growth Revenue=+6.9%
Additional Sources for TECH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle